Ann Gils Selected Research

Infliximab (Remicade)

1/2022	Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.
10/2021	The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.
1/2021	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease.
10/2020	Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients.
1/2020	Anti-infliximab antibodies: How to compare old and new data?
1/2020	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
1/2020	Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
1/2019	Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
1/2019	Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
1/2019	Optimising infliximab induction dosing for patients with ulcerative colitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ann Gils Research Topics

Disease

38	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 06/2013
28	Crohn Disease (Crohn's Disease) 01/2021 - 02/2012
24	Ulcerative Colitis 10/2022 - 06/2013
10	Neoplasms (Cancer) 10/2021 - 08/2003
8	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2020 - 01/2016
8	Cardiovascular Diseases (Cardiovascular Disease) 06/2013 - 01/2003
7	Necrosis 03/2020 - 03/2016
5	Inflammation (Inflammations) 10/2020 - 12/2005
5	Thrombosis (Thrombus) 01/2017 - 07/2002
5	Thromboembolism 02/2015 - 04/2011
4	Stroke (Strokes) 01/2016 - 04/2007
3	Ulcer 01/2020 - 01/2018
3	Rheumatoid Arthritis 01/2019 - 01/2015
3	Ischemic Stroke 01/2016 - 04/2007
3	Atherosclerosis 01/2016 - 10/2003
2	Body Weight (Weight, Body) 01/2021 - 09/2019
2	Venous Thromboembolism 10/2020 - 11/2014
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2016 - 02/2015
1	Autoimmune Diseases (Autoimmune Disease) 07/2022
1	Infections 10/2021
1	Psoriatic Arthritis 01/2019
1	Metrorrhagia (Spotting) 12/2018
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018
1	Rupture 01/2017
1	Abdominal Aortic Aneurysm 01/2017
1	Multiple Sclerosis 01/2017
1	Rheumatic Diseases (Rheumatism) 01/2017
1	Ankylosing Spondylitis 03/2016
1	Eczema 01/2016
1	Disease Progression 01/2016
1	Human Influenza (Influenza) 01/2016
1	Infarction (Infarctions) 01/2016
1	Brain Ischemia (Cerebral Ischemia) 01/2016
1	Cerebral Infarction 01/2016
1	Hemorrhage 02/2015
1	Endotoxemia 04/2012

Drug/Important Bio-Agent (IBA)

36	Infliximab (Remicade)FDA Link 01/2022 - 02/2012
24	Pharmaceutical PreparationsIBA 10/2022 - 06/2013
15	Plasminogen Activator Inhibitor 1IBA 01/2016 - 07/2002
14	AntibodiesIBA 09/2020 - 07/2011
14	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 04/2014
12	vedolizumabIBA 10/2022 - 12/2017
10	Monoclonal AntibodiesIBA 09/2020 - 04/2011
9	Adalimumab (Humira)FDA Link 07/2022 - 02/2012
9	Biological ProductsIBA 11/2019 - 03/2016
7	golimumab FDA Link 01/2021 - 05/2016
6	Plasminogen Activators (Plasminogen Activator)IBA 01/2016 - 01/2003
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2016
5	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 01/2016 - 04/2007
5	FibrinIBA 01/2016 - 12/2005
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 06/2013 - 03/2004
4	VitronectinIBA 06/2013 - 06/2003
3	Immunologic Factors (Immunomodulators)IBA 10/2021 - 03/2015
3	Biosimilar PharmaceuticalsIBA 01/2020 - 01/2017
3	Ustekinumab (CNTO 1275)FDA Link 10/2019 - 01/2018
3	Peptides (Polypeptides)IBA 01/2016 - 02/2006
3	Plasminogen InactivatorsIBA 07/2014 - 06/2003
3	SerpinsIBA 07/2010 - 08/2003
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2021 - 01/2020
2	guselkumabIBA 09/2020 - 11/2019
2	CT-P13IBA 01/2020 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 03/2016
2	IntegrinsIBA 01/2018 - 06/2016
2	Certolizumab Pegol FDA Link 01/2018 - 12/2017
2	CytokinesIBA 10/2017 - 04/2014
2	EnzymesIBA 05/2016 - 09/2015
2	ImmunosorbentsIBA 05/2016 - 09/2015
2	Fibrinogen (Factor I)FDA Link 01/2016 - 12/2005
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 10/2003
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2016 - 02/2015
2	Tumor Necrosis Factor InhibitorsIBA 06/2015 - 01/2015
2	Thromboplastin (Tissue Factor)IBA 02/2015 - 05/2014
2	AntigensIBA 03/2011 - 02/2006
1	SteroidsIBA 10/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2022
1	Interleukin-23 (Interleukin 23)IBA 09/2020
1	Neutralizing AntibodiesIBA 09/2020
1	secukinumabIBA 10/2019
1	Interleukin-12 (IL 12)IBA 07/2019
1	C-Reactive ProteinIBA 12/2018
1	AutoantibodiesIBA 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	Polysaccharides (Glycans)IBA 01/2018
1	Etanercept (Enbrel)FDA Link 06/2017
1	Prostaglandins AIBA 06/2017
1	Angiotensin IIIBA 01/2017
1	Fibrinolysin FDA Link 01/2017
1	5- amino- 2- ((1- n- propyl- 1H- imidazol- 4- yl)methyl)pentanoic acidIBA 01/2017
1	neonatal Fc receptorIBA 10/2016
1	Genetic Markers (Genetic Marker)IBA 01/2016
1	estropipate (Ogen)FDA LinkGeneric 01/2016
1	NucleoproteinsIBA 01/2016
1	von Willebrand FactorIBA 01/2016
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 03/2015
1	Thrombin FDA Link 02/2015
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 07/2014
1	ProlactinIBA 07/2014

Therapy/Procedure

24	Therapeutics 10/2022 - 08/2003
3	Biological Therapy 10/2019 - 09/2015
1	Colectomy 09/2016